Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors
Terminated · Phase 1, Phase 2 · NCT04717375
Conditions: Cancer, Neoplasm
At a glance
- Research payments reported, 2025
- $612,277
- U.S. investigators named
- 8
- Sites paid
- 12
- Planned or actual enrollment
- 125
About the trial
- Sponsor
- Sanofi
- Tested
- SAR444881 (drug), Pembrolizumab (drug), Cetuximab (drug), Carboplatin (drug), Pemetrexed (drug)
- Dates
- Started 2021-04-11; completion 2025-07-02
- Results posted
- Yes
The study enrolled advanced cancer participants with unresectable or metastatic disease who were refractory to or were not candidates for standard approved therapy. The study comprised of two parts - a dose escalation phase (Part 1) and a dose optimization/expansion phase (Part 2). Part 1 was comprised of three sub-parts: SAR444881 administered alone (Sub-Part 1A), SAR444881 administered in combination with pembrolizumab (Sub-Part 1B), and SAR444881 administered in combination with cetuximab (Sub-Part 1C). Part 2 was composed of two sub-parts: a dose optimization part where up to two doses of SAR444881 per indication were administered in combination with pembrolizumab, cetuximab, and/or c…
From ClinicalTrials.gov, last updated 2026-09-29. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $612,277 in research payments for this study in 2025 (105 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Mitesh J. Borad, MD Hematology & Oncology · Scottsdale, AZ
- Marwan G. Fakih, MD Medical Oncology · Duarte, CA
- Christopher Lieu, MD Medical Oncology · Aurora, CO
- Gopal R. Kunta, M.D. Hematology & Oncology · Clermont, FL
- Abdelaziz Elhaddad, MD Medical Oncology · Des Moines, IA
- John T. Hamm, M.D. Medical Oncology · Louisville, KY
- Patricia M. Lorusso, DO Medical Oncology · Detroit, MI
- Zhaohui Jin, M.D. Medical Oncology · Rochester, MN
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Yale University $182,930
- Mayo Clinic School of Continuous Professional Development $103,268
- Alpha Clinical Research Centers Llc $78,321
- Regents of University of Coloradoschool of Medicine Attn S Pearson General Internal Medicine $52,617
- Mayo Clinic Hospital, AZ $51,706
- Mayo Clinic,, Mayo School of Continuous Professional Development,mayo Building 1756e $36,839
- Exigent Research Llc $36,200
- Norton Healthcare,inc $30,695
- City of Hope National Medical Ctr $15,762
- Norton Healthcare, Inc $13,774
- Regents of the University of Colorado $9,956
- Norton Healthcare Inc $209
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.